Ken Griffin Pliant Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 16,900 shares of PLRX stock, worth $28,730. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,900

Previous 18,800 10.11%

Holding current value

$28,730

Previous $210,000 5.71%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$10.55 - $15.7 $3.87 Million - $5.76 Million	366,635 Added 1045.91%	401,689 $5.29 Million
Q3 2024 Nov 14, 2024	SELL	$10.52 - $14.35 $4.16 Million - $5.68 Million	-395,658 Reduced 91.86%	35,054 $392,000
Q2 2024 Aug 14, 2024	SELL	$10.58 - $15.61 $13.4 Million - $19.8 Million	-1,271,034 Reduced 74.69%	430,712 $4.63 Million
Q1 2024 May 15, 2024	BUY	$14.14 - $19.59 $1.74 Million - $2.41 Million	123,232 Added 7.81%	1,701,746 $25.4 Million
Q4 2023 Feb 14, 2024	BUY	$12.85 - $19.15 $750,902 - $1.12 Million	58,436 Added 3.84%	1,578,514 $28.6 Million
Q3 2023 Nov 14, 2023	SELL	$14.58 - $20.15 $1.35 Million - $1.87 Million	-92,829 Reduced 5.76%	1,520,078 $26.4 Million
Q2 2023 Aug 14, 2023	BUY	$18.12 - $30.56 $9.03 Million - $15.2 Million	498,079 Added 44.68%	1,612,907 $29.2 Million
Q1 2023 May 15, 2023	BUY	$18.73 - $36.26 $2.32 Million - $4.49 Million	123,707 Added 12.48%	1,114,828 $29.7 Million
Q4 2022 Feb 14, 2023	BUY	$17.0 - $25.43 $9.74 Million - $14.6 Million	573,233 Added 137.17%	991,121 $19.2 Million
Q3 2022 Nov 14, 2022	SELL	$7.67 - $24.23 $7.4 Million - $23.4 Million	-965,439 Reduced 69.79%	417,888 $8.73 Million
Q2 2022 Aug 15, 2022	BUY	$4.11 - $8.75 $23,916 - $50,916	5,819 Added 0.42%	1,383,327 $11.1 Million
Q1 2022 May 16, 2022	BUY	$7.01 - $14.1 $283,077 - $569,386	40,382 Added 3.02%	1,377,508 $9.66 Million
Q4 2021 Feb 14, 2022	BUY	$12.27 - $18.26 $107,485 - $159,957	8,760 Added 0.66%	1,337,126 $18.1 Million
Q3 2021 Nov 15, 2021	BUY	$16.48 - $28.98 $2.14 Million - $3.77 Million	129,961 Added 10.84%	1,328,366 $22.4 Million
Q2 2021 Aug 16, 2021	SELL	$28.05 - $37.69 $666,888 - $896,079	-23,775 Reduced 1.95%	1,198,405 $34.9 Million
Q1 2021 May 17, 2021	SELL	$24.52 - $40.23 $247,112 - $405,437	-10,078 Reduced 0.82%	1,222,180 $48.1 Million
Q4 2020 Feb 16, 2021	BUY	$19.89 - $32.99 $56,189 - $93,196	2,825 Added 0.23%	1,232,258 $28 Million
Q3 2020 Nov 16, 2020	SELL	$21.54 - $29.53 $72,094 - $98,836	-3,347 Reduced 0.27%	1,229,433 $27.8 Million
Q2 2020 Aug 14, 2020	BUY	$21.3 - $35.26 $26.3 Million - $43.5 Million	1,232,780 New	1,232,780 $40 Million

Others Institutions Holding PLRX

# of Institutions

175

Shares Held

64.8M

Call Options Held

228K

Put Options Held

772K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $82.8M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account